Novartis: Mayzent set for approval in Europe

(CercleFinance.com) - European regulators on Friday ruled that the benefits of Novartis' secondary progressive multiple sclerosis drug Mayzent outweigh risks, clearing the way for its future approval in Europe.


The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today adopted a positive opinion for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS).

It is estimated that up to 80% of patients will eventually transition from relapsing-remitting multiple sclerosis (RRMS) - the most common form of the disease - to SPMS.

Copyright (c) 2019 CercleFinance.com. All rights reserved.